Determination of coagulation-fibrinolytic system markers in patients with malignant tumor and its role

doi:10.3969/j.issn.1673-8640.2018.08.012

Abstract

Abstract:

Objective To investigate the relationships of plasma thrombomodulin（TM）,thrombin-antithrombin complex（TAT）,plasmin-alpha 2 plasmin inhibitor complex（PIC） and tissue plasminogen activator-plasminogen activator inhibitor-1 complex（t-PAI-C） with tumors.Methods The levels of plasma TM,TAT,PIC and t-PAI-C were determined by chemiluminescence enzyme immunoassay in 164 malignant tumor patients（81 cases of respiratory tract cancer and 83 cases of gastrointestinal cancer） and 52 healthy subjects（healthy control group）. The difference of plasma TM,TAT,PIC and t-PAI-C between malignant tumor and healthy control groups was evaluated,and the difference between tumor metastasis and non-tumor metastasis groups was analyzed as well.Results The levels of TM,TAT,PIC and t-PAI-C in malignant tumor group were higher than those in healthy control group（P<0.01）. The levels of TM,TAT and PIC in respiratory tract cancer group were higher than those in healthy control group（P<0.01）,and there was no statistical significance for t-PAI-C between the 2 groups（P>0.05）. There was statistical significance for TM,TAT,PIC and t-PAI-C between gastrointestinal cancer group and healthy control group（P<0.01）. In malignant tumor group,TAT,PIC and t-PAI-C were higher in tumor metastasis group than those in non-tumor metastasis group（P<0.01）,while TM had no statistical significance between the 2 groups（P>0.05）. In respiratory tract cancer and gastrointestinal cancer groups,the levels of TAT,PIC and t-PAI-C in tumor metastasis group were higher than those in non-tumor metastasis group（P<0.01）,while there was no statistical significance for TM（P>0.05）.Conclusions Malignant tumor patients have different degrees of vascular endothelial injury and coagulation-fibrinolytic system disorder. Plasma TM,TAT,PIC and t-PAI-C can be used as indicators for malignant tumor progression,curative effect and prognosis.

Key words: Thrombomodulin, Thrombin-antithrombin complex, Plasmin-alpha 2 plasmin inhibitor complex, Tissue plasminogen activator-plasminogen activator inhibitor-1 complex, Malignant tumor

CLC Number:

R446.1

CHEN Wenxin, LI Qiang, XUE Yingjun, SHAO Huaqing, LI Zhen, LU Wenqian, HU Xiaobo. Determination of coagulation-fibrinolytic system markers in patients with malignant tumor and its role[J]. Laboratory Medicine, 2018, 33(8): 722-726.

Figures/Tables 2

References 20

[1]	NIELSEN V G,MATIKA R W,LEY M L,et al.Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast,lung,pancreas and colon cancer[J]. Blood Coagul Fibrinolysis,2014,25(3):248-253.
[2]	FALANGA A,TARTARI C J,MARCHETTI M.Microparticles in tumor progression[J]. Thromb Res,2012,129(Suppl 1):S132-S136.
[3]	RUF W,DISSE J,>CARNEIRO-LOBO T C,et al. Tissue factor and cell signalling in cancer progression and thrombosis[J]. J Thromb Haemost,2011,9(Suppl 1):306-315.
[4]	ZWICKER J I.Predictive value of tissue factor bearing micropaticles in cancer associated thrombosis[J]. Thromb Res,2010,125(Suppl 2):S89-S91.
[5]	OSHIMA H, OSHIMA M.The inflammatory network in the gastrointestinal tumor microenvironment:lessons from mouse models[J]. J Gastroenterol,2012,47(2):97-106.
[6]	GIL-BERNABE A M,LUCOTTI S,MUSCHEL R J. Coagulation and metastasis:what dose the experimental literature tell us[J]. Br J Haematol,2013,162(4):433-441.
[7]	HO-TIN-NOÉ B,DEMERS M,WAGNER D D. How platelets safeguard vascular integrity[J]. J Thromb Haemost,2011,9(Suppl 1):56-65.
[8]	COUPLAND L A,CHONG B H,PARISH C R.Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells[J]. Cancer Res,2012,72(18):4662-4671.
[9]	GIL-BERNABÉ A M,FERJANCIC S,TLALKA M,et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice[J]. Blood,2012,119(13):3164-3175.
[10]	AZHAR A,SINGH P,RASHID Q.Antiangiogenic function of antithrombin is dependent on its conformational variation:implication for other serpins[J]. Protein Pept Lett,2013,20(4):403-411.
[11]	OLSSON E,SVARTLING N,ASKO-SELJAVAARA S,et al.Activation of coagulation and fibrinolysis during reconstructive microsurgery in patients with cancer[J]. Microsurgery,2001,21(5):208-213.
[12]	MATSUYAMA W,HASHIGUCHI T,MIZOGUCHI A,et al.Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer[J]. Chest,2000,118(4) :948-951.
[13]	CALIFANO F,GIOVANNIELLO T,Pantone P.Clinical importance of thrombomodulin serum levels[J]. Eur Rev Med Pharmacol Sci,2000,4(3):59-66.
[14]	HAYASHI T,NISHIOKA J,KAMADA H,et al.Characterization of a novel human protein C inhibitor (PCI) gene transgenic mouse useful for studying the role of PCI in physiological and pathological conditions[J]. J Thromb Haemost,2004,2(6):949-961.
[15]	AKITA N,MA N,OKAMOTO T.Host protein C inhibitor inhibits tumor growth,but promotes tumor metastasis,which is closely correlated with hypercoagulability[J]. Thromb Res,2015,135(6):1203-1208.
[16]	吴艳梅. 血栓调节蛋白一种新型肿瘤标志物[J]. 医药论坛杂志,2008,29(2):124-127.
[17]	MCMAHON B J,KWAAN H C.Components of the plasminogen-plasmin system as biologic markers for cancer[J]. Adv Exp Med Biol,2015,867:145-156.
[18]	DANØ K,BEHRENDT N,HØYER-HANSEN G,et al. Plasminogen activation and cancer[J]. Thromb Haemost,2005,93(4):676-681.
[19]	KWAAN H C,MCMAHON B.The role of plasminogen-plasmin system in cancer[J]. Cancer Treat Res,2009,148:43-66.
[20]	DERYUGINA E I,QUIGLEY J P.Cell surface remodeling by plasmin:a new function for an old enzyme[J]. J Biomed Biotechnol,2012,2012:564259.

组别	例数	TM（ng/mL）	TAT（μg/mL）	PIC（IU/mL）	t-PAI-C（ng/mL）
恶性肿瘤组	164	9.10（7.95~10.68）^*	1.10（0.80~2.20）^*	0.73（0.54~1.08）^*	7.00（5.00~9.08）^*
呼吸道肿瘤组	81	8.90（7.65~10.15）^*	1.10（0.80~1.90）^*	0.71（0.54~1.17）^*	7.00（5.05~8.75）
消化道肿瘤组	83	9.50（8.20~11.20）^*	1.20（0.80~3.10）^*	0.74（0.56~0.97）^*	7.30（4.80~9.5）^*
正常对照组	52	7.85（6.63~9.18）	0.95（0.50~1.40）	0.49（0.39~0.60）	6.45（4.43~7.8）

组别	例数	TM（ng/mL）	TAT（μg/mL）	PIC（IU/mL）	t-PAI-C（ng/mL）
恶性肿瘤组	164	9.10（7.95~10.68）^*	1.10（0.80~2.20）^*	0.73（0.54~1.08）^*	7.00（5.00~9.08）^*
呼吸道肿瘤组	81	8.90（7.65~10.15）^*	1.10（0.80~1.90）^*	0.71（0.54~1.17）^*	7.00（5.05~8.75）
消化道肿瘤组	83	9.50（8.20~11.20）^*	1.20（0.80~3.10）^*	0.74（0.56~0.97）^*	7.30（4.80~9.5）^*
正常对照组	52	7.85（6.63~9.18）	0.95（0.50~1.40）	0.49（0.39~0.60）	6.45（4.43~7.8）

组别	例数	TM（ng/mL）	TAT（μg/mL）	PIC（IU/mL）	t-PAI-C（ng/mL）
恶性肿瘤组
恶性肿瘤无转移者	76	8.95（7.90~10.30）	0.90（0.60~1.35）	0.56（0.43~0.74）	6.10（4.23~8.30）
恶性肿瘤有转移者	88	9.25（8.10~11.25）	1.80（1.00~3.30）^*	0.91（0.70~1.56）^*	7.85（5.63~10.28）^*
呼吸道肿瘤组
恶性肿瘤无转移者	41	8.70（7.65~9.95）	0.90（0.60~1.30）	0.55（0.43~0.69）	6.20（4.60~8.05）
恶性肿瘤有转移者	40	9.05（7.68~10.50）	1.55（1.00~2.90）^*	1.07（0.72~1.56）^*	7.75（5.55~9.88）^*
消化道肿瘤组
恶性肿瘤无转移者	35	9.40（8.30~10.70）	0.90（0.60~1.40）	0.57（0.41~0.82）	6.00（3.10~8.60）
恶性肿瘤有转移者	48	9.55（8.13~11.40）	1.90（1.00~4.28）^*	0.84（0.67~1.58）^*	7.9（5.65~11.08）^*

组别	例数	TM（ng/mL）	TAT（μg/mL）	PIC（IU/mL）	t-PAI-C（ng/mL）
恶性肿瘤组
恶性肿瘤无转移者	76	8.95（7.90~10.30）	0.90（0.60~1.35）	0.56（0.43~0.74）	6.10（4.23~8.30）
恶性肿瘤有转移者	88	9.25（8.10~11.25）	1.80（1.00~3.30）^*	0.91（0.70~1.56）^*	7.85（5.63~10.28）^*
呼吸道肿瘤组
恶性肿瘤无转移者	41	8.70（7.65~9.95）	0.90（0.60~1.30）	0.55（0.43~0.69）	6.20（4.60~8.05）
恶性肿瘤有转移者	40	9.05（7.68~10.50）	1.55（1.00~2.90）^*	1.07（0.72~1.56）^*	7.75（5.55~9.88）^*
消化道肿瘤组
恶性肿瘤无转移者	35	9.40（8.30~10.70）	0.90（0.60~1.40）	0.57（0.41~0.82）	6.00（3.10~8.60）
恶性肿瘤有转移者	48	9.55（8.13~11.40）	1.90（1.00~4.28）^*	0.84（0.67~1.58）^*	7.9（5.65~11.08）^*